SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

TransCode Therapeutics Begins Strategic Review of Oncology Portfolio

TransCode Therapeutics says it has launched a formal process to explore opportunities to maximize value across the company and its oncology portfolio, including lead candidate TTX-MC138.

RNAZ
SquawkNews Desk

Related stories

Howmet Executive Says Gas Turbine Capacity Is Sold Out Through 2031 Howmet's executive says major gas turbine customers report 2031 capacity is sold out; 2032 capacity will likely sell out in the next one or two quarters. M impact | EQUITY | Oct 29, 2026, 02:37 PM UTC IndiGo Says Fare Increases Inevitable as Fuel Costs Rise IndiGo said fare increases are inevitable as fuel costs rise. L impact | EQUITY | Oct 29, 2026, 02:37 PM UTC Sanrio Apologizes, Scraps Japan TV Tie-Up After China Anger Sanrio apologized after criticism in China and scrapped a Japan television tie-up, according to the headline. L impact | EQUITY | Oct 29, 2026, 02:37 PM UTC Restaurant Brands International Reports Mixed Quarterly Results Restaurant Brands International reported mixed quarterly financial results. The report says consumer spending on discretionary items such as dining out remains weak. M impact | EQUITY | Oct 29, 2026, 02:36 PM UTC FERC Approves Rio Grande LNG Capacity Uprate; NextDecade Posts Quarterly Profit NextDecade shares jumped after FERC approved a capacity uprate at the Rio Grande LNG project. The company also posted a quarterly profit. M impact | EQUITY | Oct 29, 2026, 02:36 PM UTC Al Tas-heelat Jordan Reports Q3 Revenue of 6.7 Million Dinars M impact | EQUITY | Oct 29, 2026, 02:36 PM UTC